ArticleFrontiers in pharmacology2025
Ethnobotanical survey of herbal medicines for anti-COVID-19 used by traditional Chinese medicine pharmacies in Taiwan.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Traditional Chinese medicine (TCM) pharmacies in Taiwan have been a vital healthcare resource in Chinese communities, with generations of accumulated TCM knowledge playing a crucial role in infectious disease prevention and treatment. However, as proprietors age and the industry declines, this valuable ethnomedicinal knowledge faces the risk of being lost. Therefore, documenting and analyzing the knowledge used by Taiwanese TCM pharmacies in combating COVID-19 is essential for the preservation and application of ethnomedicine. Methods: This study employed a stratified sampling method to survey 106 TCM pharmacies in Taiwan, collecting 61 TCM formulae against COVID-19. The medicinal materials were compiled, and analysis were conducted using relative frequency of citation (RFC) and the Phi correlation coefficient to examine the relationships among TCMs. Furthermore, cluster analysis was applied to establish TCM combination patterns. Results: This study recorded a total of 70 medicinal materials and identified 30 commonly used ones, categorizing them into four major groups: Group A (heat-clearing and detoxifying): As similar as NRICM101, suitable for moderate to severe cases. Group B (heat-clearing and tonifying): Suitable for mild cases, with both antiviral and immune-boosting effects. Group C (symptom relief): Primarily used for relieving cough, expelling phlegm, and alleviating discomfort. Group D (tonifying and strengthening): Suitable for uninfected individuals to enhance immunity. Discussion: This study successfully documented and analyzed the TCM usage patterns of Taiwanese TCM pharmacies in combating COVID-19, revealing their alignment with modern TCM theories. The findings not only contribute to the preservation of ethnobotanical knowledge but also serve as a reference for developing herbal prevention strategies and healthcare products, ensuring that traditional medical wisdom can play a greater role within the modern healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.